Clovis Oncology, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Patrick Mahaffy
- Full Time Employees
- 413
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5500 Flatiron Pkwy Unit 100 Boulder CO United States of America 80301
- IPO Date
- Nov 16, 2011
- CIK
- 0001466301
- Website
- clovisoncology.com
- Similar Companies
- Business
- Clovis Oncology, Inc. is a biopharmaceutical company specializing in acquiring, developing, and commercializing anti-cancer agents primarily in the United States, Europe, and additional international markets. The company’s main products include Rubraca, an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), marketed for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, primary peritoneal cancer, and metastatic castration-resistant prostate cancer. Clovis also develops FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein (FAP), and Lucitanib, an investigational oral angiogenesis inhibitor targeting VEGFR1-3, PDGFR α/β, and FGFR1-3 receptor pathways, which is being studied in breast cancer and non-small cell lung cancer indications. Founded in 2009 and headquartered in Boulder, Colorado, Clovis Oncology operates in the biotechnology and pharmaceutical sectors focusing on oncology treatments. The company conducts global clinical trials and development programs aimed at specific subsets of cancer populations, often in partnership with other firms. In recent major developments, Clovis Oncology filed for Chapter 11 bankruptcy in December 2022 and subsequently sold rights to its FAP-2286 asset to Novartis Innovative Therapies AG for $50 million upfront as part of its restructuring. It also engaged in a deal to sell its approved cancer drug Rubraca to a privately held Austrian company amid ongoing auctions linked to bankruptcy proceedings. The company has been actively submitting applications for label expansions of Rubraca in the US and Europe, notably for first-line maintenance treatment of ovarian cancer based on promising clinical trial results. Clovis is also advancing its clinical pipeline with ongoing Phase II and III studies for its investigational agents, including the exploration of Lucitanib in multiple cancer indications and combinations with immunotherapies. Overall, Clovis Oncology provides a portfolio of targeted cancer therapies with a focus on molecularly defined indications and precision medicine, supported by extensive clinical development and strategic asset transactions in recent years that reflect its operational and financial restructuring efforts.
Greene Concepts and CVYE Set to Empower 100 Young Entrepreneurs at Clovis, CA Children's Business Fair
Olivier Clovis Scaling Business Launches Sales Funnel Coaching Program to Help Entrepreneurs Scale Online Businesses
The 7 Best Penny Stocks to Buy Now
Bet on 5 Top Stocks With Rising P/E
Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis
Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid
CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy
Clovis Oncology stock slides 10% premarket after company files for bankruptcy
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286
Dear CLVS Stock Fans, Get Ready for a Bankruptcy Filing
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why
Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)
7 Stocks to Sell Right Now
Best Penny Stocks To Buy? 7 To Watch Under $1 Right Now
Clovis Oncology (CLVS) Stock Pops After Bankruptcy Warning
Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing
Why Is Clovis Oncology (CLVS) Stock Down 72% Today?
Clovis Oncology stock slides 75% after biotech warns it will run out of cash by January of 2023
Clovis Oncology: Looking Like An Acquisition Target After Recent Company Updates